Abcellera Biologics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $17,084 | $4,235 | $5,050 | $6,507 |
Gross Profit | 17,084 | -38,261 | -8,851 | -31,788 |
EBITDA | -38,833 | -39,602 | -33,728 | -51,877 |
EBIT | -45,893 | -44,933 | -47,629 | -90,172 |
Net Income | -34,727 | -45,621 | -34,210 | -51,107 |
Net Change In Cash | 17,084 | 4,235 | 5,050 | 6,507 |
Free Cash Flow | -45,769 | -22,190 | -23,630 | -47,398 |
Cash | 92,437 | 159,266 | 156,325 | 126,640 |
Basic Shares | 298,508 | 297,692 | 295,757 | 294,851 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $28,833 | $38,025 | $485,424 | $11,611 |
Gross Profit | -68,166 | 7,131 | 418,988 | 11,611 |
EBITDA | -204,148 | -192,158 | 272,201 | -154 |
EBIT | -301,147 | -223,052 | 239,099 | -2,001 |
Net Income | -162,857 | -146,398 | 158,519 | -2,210 |
Net Change In Cash | 28,833 | 38,025 | 485,424 | 11,611 |
Cost of Revenue | -76,893 | -91,549 | ||
Free Cash Flow | -186,952 | -121,384 | 204,700 | 186,132 |
Cash | 156,325 | 133,320 | 386,535 | 476,142 |
Basic Shares | 294,327 | 289,166 | 314,827 | 318,294 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.12 |
2025-03-31 | -$0.15 |
2024-12-31 | -$0.12 |
